© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 16, 1329-1336,
August 16, 2000
© 2000 Oxford University Press
Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis
Affiliations of authors: G. J. Byrne, A. Ghellal, J. Iddon, A. D. Blann, V. Venizelos, N. J. Bundred, Department of Academic Surgery, University Hospital of South Manchester, U.K.; S. Kumar, Department of Pathological Science, University of Manchester; A. Howell, Cancer Research Campaign Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, U.K.
Correspondence to: Nigel J. Bundred, M.D., Reader in Surgical Oncology, University Hospital of South Manchester, Nell Lane, Manchester, M20 8LR, U.K. (e-mail: bundredn{at}fs1.with.man.ac.uk).
Background: Angiogenesis, the development of new blood vessels from pre-existing vasculature, is a prerequisite for tumor growth and metastasis. Surrogate markers for angiogenesis would be useful for studying the effectiveness of antiangiogenesis drugs. We examined the potential of three serum glycoproteins—vascular cell adhesion molecule-1 (VCAM-1), endothelial selectin (E-selectin), and von Willebrand factor (VWF)—to serve as markers for angiogenesis. Methods: Preoperative serum levels of VCAM-1, E-selectin, and VWF were measured by enzyme-linked immunosorbent assay in 93 women with early breast cancer and were compared with microvessel density in each tumor, histologic features, and recurrence after surgery. Serum samples were taken from 55 women with advanced breast cancer who were commencing hormonal therapy, both immediately before therapy and 3 months later. Changes in serum levels of VCAM-1, E-selectin, and VWF were compared with the response of the disease to hormonal therapy assessed 6 months after the start of hormone therapy or at disease progression. All P values are two-sided. Results: In women with early breast cancer, serum levels of VCAM-1 (but not of E-selectin or VWF) correlated closely with microvessel density in tumors (r = .65; P<.001), and women who developed early recurrence had higher preoperative levels of serum VCAM-1 than those who remained disease free (P = .01). Serum VCAM-1 levels rose in women with advanced breast cancer whose disease progressed (P<.001) but remained unchanged or fell in women with advanced breast cancer whose disease remained stable or showed a partial response to hormonal therapy. Conclusion: Serum VCAM-1 appears to be a surrogate marker of angiogenesis in breast cancer. Its measurement may, therefore, help in the assessment of antiangiogenesis drugs currently in phase II trials.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Baar, P. Silverman, J. Lyons, P. Fu, F. Abdul-Karim, N. Ziats, J. Wasman, P. Hartman, J. Jesberger, L. Dumadag, et al. A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers Clin. Cancer Res., May 15, 2009; 15(10): 3583 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Shioi, A. Komiya, K. Hattori, Y. Huang, F. Sano, T. Murakami, N. Nakaigawa, T. Kishida, Y. Kubota, Y. Nagashima, et al. Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients Clin. Cancer Res., December 15, 2006; 12(24): 7339 - 7346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kilic, L. Oliveira-Ferrer, J.-H. Wurmbach, S. Loges, F. Chalajour, S. N. Vahid, J. Weil, M. Fernando, and S. Ergun Pro-angiogenic Signaling by the Endothelial Presence of CEACAM1 J. Biol. Chem., January 21, 2005; 280(3): 2361 - 2369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, V. A. Anwuri, D. J. Lamb, N. V. Shah, T. M. Wheeler, and K. M. Slawin Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy J. Clin. Oncol., May 1, 2004; 22(9): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H G Augustin Translating angiogenesis research into the clinic: the challenges ahead Br. J. Radiol., December 1, 2003; 76(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kalomenidis, K. H. Mohamed, K. B. Lane, R. S. Peebles, R. Barnette, R. M. Rodriguez, and R. W. Light Pleural Fluid Levels of Vascular Cell Adhesion Molecule-1 Are Elevated in Eosinophilic Pleural Effusions Chest, July 1, 2003; 124(1): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakao, T. Kuwano, T. Ishibashi, M. Kuwano, and M. Ono Synergistic Effect of TNF-{alpha} in Soluble VCAM-1-Induced Angiogenesis Through {alpha}4 Integrins J. Immunol., June 1, 2003; 170(11): 5704 - 5711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, K. R. Hess, H. T. Tran, J. E. Tseng, N. A. Mullani, C. Charnsangavej, T. Madden, D. W. Davis, D. J. McConkey, M. S. O'Reilly, et al. Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors J. Clin. Oncol., September 15, 2002; 20(18): 3792 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dowlati, K. Robertson, M. Cooney, W. P. Petros, M. Stratford, J. Jesberger, N. Rafie, B. Overmoyer, V. Makkar, B. Stambler, et al. A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer Cancer Res., June 1, 2002; 62(12): 3408 - 3416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mancuso, A. Burlini, G. Pruneri, A. Goldhirsch, G. Martinelli, and F. Bertolini Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood, June 1, 2001; 97(11): 3658 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Braybrooke, K. J. O’Byrne, D. J. Propper, A. Blann, M. Saunders, N. Dobbs, C. Han, J. Woodhull, K. Mitchell, J. Crew, et al. A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis Clin. Cancer Res., December 1, 2000; 6(12): 4697 - 4704. [Abstract] [Full Text]
|
|